Design, Synthesis, Structure-Activity Relationships, and Docking Studies of 1-(γ-1,2,3-Triazol Substituted Prolyl)-(S)-3,3-Difluoropyrrolidines as a Novel Series of Potent and Selective Dipeptidyl Peptidase-4 Inhibitors

Chemical Biology and Drug Design

Volumn 81, Issue 2, 2013, Pages 198-207

  Zhang, Lei ^a   Su, Mingbo ^a   Li, Jingya ^a   Ji, Xun ^a   Wang, Jiang ^a   Li, Zeng ^a   Li, Jia ^a   Liu, Hong ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Dipeptidyl peptidase 4; Inhibitor; Molecular docking; Triazole; Type 2 diabetes

Indexed keywords

1 [5 [(3,3 DIFLUOROPYRROLIDIN 1 YL)CARBONYL]PYRROLIDIN 3 YL] 4 (2 FLUOROPHENYL) 1H 1,2,3 TRIAZOLE; 1 [5 [(3,3 DIFLUOROPYRROLIDIN 1 YL)CARBONYL]PYRROLIDIN 3 YL] 4 (3 FLUOROPHENYL) 1H 1,2,3 TRIAZOLE; 1 [5 [(3,3 DIFLUOROPYRROLIDIN 1 YL)CARBONYL]PYRROLIDIN 3 YL] 4 (4 FLUORO 3 METHYLPHENYL) 1H 1,2,3 TRIAZOLE; 1 [5 [(3,3 DIFLUOROPYRROLIDIN 1 YL)CARBONYL]PYRROLIDIN 3 YL] 4 (4 FLUOROPHENYL) 1H 1,2,3 TRIAZOLE; 1 [5 [(3,3 DIFLUOROPYRROLIDIN 1 YL)CARBONYL]PYRROLIDIN 3 YL] 4 (4 METHOXYPHENYL) 1H 1,2,3 TRIAZOLE; 1 [5 [(3,3 DIFLUOROPYRROLIDIN 1 YL)CARBONYL]PYRROLIDIN 3 YL] 4 (4 PHENYLPHENYL) 1H 1,2,3 TRIAZOLE; 1 [5 [(3,3 DIFLUOROPYRROLIDIN 1 YL)CARBONYL]PYRROLIDIN 3 YL] 4 (6 METHOXYNAPHTHALEN 2 YL) 1H 1,2,3 TRIAZOLE; 1 [5 [(3,3 DIFLUOROPYRROLIDIN 1 YL)CARBONYL]PYRROLIDIN 3 YL] 4 [2 (TRIFLUOROMETHYL)PHENYL] 1H 1,2,3 TRIAZOLE; 1 [5 [(3,3 DIFLUOROPYRROLIDIN 1 YL)CARBONYL]PYRROLIDIN 3 YL] 4 [4 (PENTYLOXY)PHENYL] 1H 1,2,3 TRIAZOLE; 1 [5 [(3,3 DIFLUOROPYRROLIDIN 1 YL)CARBONYL]PYRROLIDIN 3 YL] 4 PHENYL 1H 1,2,3 TRIAZOLE; 1,2,3 TRIAZOLE DERIVATIVE; 2 [1 [5 [(3,3 DIFLUOROPYRROLIDIN 1 YL)CARBONYL]PYRROLIDIN 3 YL] 1H 1,2,3 TRIAZOLE 4 YL]PYRIDINE; 3 [1 [5 [(3,3 DIFLUOROPYRROLIDIN 1 YL)CARBONYL]PYRROLIDIN 3 YL] 1H 1,2,3 TRIAZOLE 4 YL]PHENOL; 4 (4 TERT BUTYLPHENYL) 1 [5 [(3,3 DIFLUOROPYRROLIDIN 1 YL)CARBONYL]PYRROLIDIN 3 YL] 1H 1,2,3 TRIAZOLE; 4 [1 [5 [(3,3 DIFLUOROPYRROLIDIN 1 YL)CARBONYL]PYRROLIDIN 3 YL] 1H 1,2,3 TRIAZOLE 4 YL]BENZONITRILE; 4 [[1 [5 [(3,3 DIFLUOROPYRROLIDIN 1 YL)CARBONYL]PYRROLIDIN 3 YL] 1H 1,2,3 TRIAZOLE 4 YL]METHOXY] 2,6 DIFLUOROBENZONITRILE; 4 BENZYL 1 [5 [(3,3 DIFLUOROPYRROLIDIN 1 YL)CARBONYL]PYRROLIDIN 3 YL] 1H 1,2,3 TRIAZOLE; [1 [5 [(3,3 DIFLUOROPYRROLIDIN 1 YL)CARBONYL]PYRROLIDIN 3 YL] 1H 1,2,3 TRIAZOLE 4 YL]DIPHENYLMETHANOL; [2 [1 [5 [(3,3 DIFLUOROPYRROLIDIN 1 YL)CARBONYL]PYRROLIDIN 3 YL] 1H 1,2,3 TRIAZOLE 4 YL]PHENYL]METHANOL; ALOGLIPTIN; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE 8; DIPEPTIDYL PEPTIDASE 9; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FIBROBLAST ACTIVATION PROTEIN; METHYL 1 [5 [(3,3 DIFLUOROPYRROLIDIN 1 YL)CARBONYL]PYRROLIDIN 3 YL] 1H 1,2,3 TRIAZOLE 4 CARBOXYLATE; PROTEIN; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG STABILITY; IC 50; IN VITRO STUDY; MOLECULAR DOCKING; PRIORITY JOURNAL; SIMULATION; STRUCTURE ACTIVITY RELATION;

BINDING SITES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HYPOGLYCEMIC AGENTS; MOLECULAR DOCKING SIMULATION; PROLINE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 84872336284     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12058     Document Type: Article

References (25)

1. Tahrani A.A., Bailey C.J., Del Prato S., Barnett A.H. (2011) Management of type 2 diabetes: new and future developments in treatment. Lancet;378:182-197.
2. Kim W., Egan J.M. (2008) The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev;60:470-512.
3. Holst J.J. (2007) The physiology of glucagon-like peptide 1. Physiol Rev;87:1409-1439.
4. Holst J.J., Vilsboll T., Deacon C.F. (2009) The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol;297:127-136.
5. Mentlein R., Gallwitz B., Schmidt W.E. (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem;214:829-835.
6. Kieffer T.J., McIntosh C.H., Pederson R.A. (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology;136:3585-3596.
7. Biftu T., Scapin G., Singh S., Feng D., Becker J.W., Eiermann G., He H. et al. (2007) Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin. Bioorg Med Chem Lett;17:3384-3387.
8. Karasik A., Aschner P., Katzeff H., Davies M.J., Stein P.P. (2008) Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin;24:489-496.
9. Stamataros G., Schneider S.H. (2011) Vildagliptin in the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother;12:1967-1973.
10. Villhauer E.B., Brinkman J.A., Naderi G.B., Burkey B.F., Dunning B.E., Prasad K., Mangold B.L., Russell M.E., Hughes T.E. (2003) 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem;46:2774-2789.
11. Augeri D.J., Robl J.A., Betebenner D.A., Magnin D.R., Khanna A., Robertson J.G., Wang A. et al. (2005) Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem;48:5025-5037.
12. Feng J., Zhang Z., Wallace M.B., Stafford J.A., Kaldor S.W., Kassel D.B., Navre M., Shi L., Skene R.J., Asakawa T., Takeuchi K., Xu R., Webb D.R., Gwaltney S.L. 2nd (2007) Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem;50:2297-2300.
13. Eckhardt M., Langkop E., Mark M., Tadayyon M., Thomas L., Nar H., Pfrengle W., Guth B., Lotz R., Sieger P., Fuchs H., Himmelsbach F. (2007) 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3, 7-dihydropurine-2, 6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem;50:6450-6453.
14. Augustyns K., Van der Veken P., Senten K., Haemers A. (2005) The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidyl aminopeptidases. Curr Med Chem;12:971-998.
15. Havale S.H., Pal M. (2009) Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. Bioorg Med Chem;17:1783-1802.
16. Ashworth D.M., Atrash B., Baker G.R., Baxter A.J., Jenkins P.D., Jones D.M., Szelke M. (1996) 2-Cyanopyrrolidides as potent, stable inhibitors of dipeptidyl peptidase IV. Bioorg Med Chem Lett;6:1163-1166.
17. Zhou C.H., Wang Y. (2012) Recent researches in triazole compounds as medicinal drugs. Curr Med Chem;19:239-280.
18. Kharb R., Yar M.S., Sharma P.C. (2011) New insights into chemistry and anti-infective potential of triazole scaffold. Curr Med Chem;18:3265-3297.
19. Kharb R., Yar M.S., Sharma P.C. (2011) Recent advances and future perspectives of triazole analogs as promising antiviral agents. Mini Rev Med Chem;11:84-96.
20. Kharb R., Sharma P.C., Yar M.S. (2011) Pharmacological significance of triazole scaffold. J Enzyme Inhib Med Chem;26:1-21.
21. Agalave S.G., Maujan S.R., Pore V.S. (2011) Click chemistry: 1, 2, 3-triazoles as pharmacophores. Chem Asian J;6:2696-2718.
22. Lankas G.R., Leiting B., Roy R.S., Eiermann G.J., Beconi M.G., Biftu T., Chan C.C. et al. (2005) Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes;54:2988-2994.
23. Dobers J., Zimmermann-Kordmann M., Leddermann M., Schewe T., Reutter W., Fan H. (2002) Expression, purification, and characterization of human dipeptidyl peptidase IV/CD26 in Sf9 insect cells. Protein Expr Purif;25:527-532.
24. Ammirati M.J., Andrews K.M., Boyer D.D., Brodeur A.M., Danley D.E., Doran S.D., Hulin B. et al. (2009) (3, 3-Difluoro-pyrrolidin-1-yl)-[(2S, 4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor. Bioorg Med Chem Lett;19:1991-1995.
25. Friesner R.A., Banks J.L., Murphy R.B., Halgren T.A., Klicic J.J., Mainz D.T., Repasky M.P., Knoll E.H., Shelley M., Perry J.K., Shaw D.E., Francis P., Shenkin P.S. (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem;47:1739-1749.